Key result
Carvedilol uniquely prevents redox-dependent cardiomyocyte β1AR downregulation and protects against doxorubicin-induced apoptosis.
Why the study?
Does carvedilol prevent redox inactivation of cardiomyocyte β1-adrenergic receptors?
Does carvedilol prevent redox inactivation of cardiomyocyte β1-adrenergic receptors?
Carvedilol uniquely prevents redox inactivation of cardiomyocyte β1-adrenergic receptors and protects against doxorubicin-induced apoptosis, providing a molecular basis for its clinical benefits in heart failure.
Hypothesis-generating for carvedilol in doxorubicin cardiotoxicity; requires clinical validation before practice change.
The mechanism that leads to a decrease in β1-adrenergic receptor (β1AR) expression in the failing heart remains uncertain. This study shows that cardiomyocyte β1AR expression and isoproterenol responsiveness decrease in response to oxidative stress. Studies of mechanisms show that the redox-dependent decrease in β1AR expression is uniquely prevented by carvedilol and not other βAR ligands. Carvedilol also promotes the accumulation of N-terminally truncated β1ARs that confer protection against doxorubicin-induced apoptosis in association with activation of protein kinase B. The redox-induced molecular controls for cardiomyocyte β1ARs and pharmacologic properties of carvedilol identified in this study have important clinical and therapeutic implications.
No takes yet. Share an insight, caveat, or question.
Park et al. (2018) studied Heart failure. Carvedilol vs. Other βAR ligands was evaluated on Cardiomyocyte β1AR expression and doxorubicin-induced apoptosis. Carvedilol uniquely prevented the redox-dependent decrease in cardiomyocyte β1-adrenergic receptor expression and protected against doxorubicin-induced apoptosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: